RHOA and non-small cell lung carcinoma: This approach also extends to NSCLC lines that express readily detectable levels of steady-state DLC1 protein, as EZH2 inhibition further increases their DLC1 protein levels and regulates RhoA-GTP in a DLC1-dependent manner.